Evolus, Inc. (NASDAQ:EOLS) Director Karah Herdman Parschauer Sells 12,888 Shares

Evolus, Inc. (NASDAQ:EOLSGet Free Report) Director Karah Herdman Parschauer sold 12,888 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total transaction of $167,415.12. Following the completion of the transaction, the director now owns 32,183 shares in the company, valued at $418,057.17. The trade was a 28.59 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Evolus Trading Up 1.9 %

Shares of EOLS opened at $13.20 on Friday. The business’s 50-day moving average price is $13.10 and its 200 day moving average price is $14.00. The stock has a market capitalization of $839.35 million, a P/E ratio of -14.51 and a beta of 1.28. Evolus, Inc. has a 1-year low of $9.25 and a 1-year high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Analyst Ratings Changes

EOLS has been the subject of a number of recent analyst reports. Barclays raised their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research note on Wednesday, March 5th. Finally, HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of Evolus in a research note on Wednesday, March 5th.

Check Out Our Latest Stock Report on Evolus

Hedge Funds Weigh In On Evolus

Institutional investors and hedge funds have recently bought and sold shares of the business. KBC Group NV purchased a new position in Evolus during the 4th quarter valued at about $49,000. IFP Advisors Inc lifted its stake in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after purchasing an additional 4,709 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Evolus in the 3rd quarter valued at $132,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Evolus in the 4th quarter valued at $106,000. Finally, Rafferty Asset Management LLC acquired a new stake in shares of Evolus in the 4th quarter valued at $115,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

About Evolus

(Get Free Report)

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

See Also

Insider Buying and Selling by Quarter for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.